Hong Kong Construction Stock News

FWD Group Holdings (SEHK:1828) has just posted its FY 2025 first half scorecard, with revenue of about US$1.5 billion and basic EPS of US$0.05. This helps set the tone for how investors may interpret the company’s sharp earnings reset over the past year. The company reported revenue of US$1.3 billion in 2H 2024 and US$1.6 billion in 1H 2024 before this latest half, while basic EPS moved from US$0.0032 in 1H 2024 and US$0.0223 in 2H 2024 to US$0.05. This progression puts a clear spotlight on...

SINOPEC Engineering (Group) (SEHK:2386) has just posted its FY 2025 numbers with first half revenue of about C¥31.6b and basic EPS of C¥0.32, set against trailing twelve month revenue of roughly C¥70.1b and EPS of C¥0.41 that frame the latest performance. Over recent periods the company has seen revenue move from around C¥28.7b in 1H 2024 to C¥31.6b in 1H 2025, while basic EPS shifted from C¥0.30 in 1H 2024 to C¥0.32 in 1H 2025. This gives investors a clear read on how the top line and EPS...

Kingboard Laminates Holdings (SEHK:1888) has reported FY 2025 first half revenue of HK$9.6b and basic EPS of HK$0.30, with the latest trailing twelve month figures showing revenue of HK$20.4b and EPS of HK$0.78 alongside earnings growth of 84.2% over the past year. Over recent periods, revenue has moved from HK$8.6b in 1H FY 2024 to HK$9.9b in 2H FY 2024 and then to HK$9.6b in 1H FY 2025. Over the same intervals, basic EPS has shifted from HK$0.23 to HK$0.19 and then to HK$0.30, presenting a...

Recent share performance and valuation context China Development Bank Financial Leasing (SEHK:1606) has drawn investor attention after a recent 1.4% daily gain, contrasting with a month return of about 4.5% decline and a past 3 months slide of roughly 11.4%. At a last close of HK$1.48 and an estimated intrinsic discount of about 75%, the leasing group, which generates CN¥16,166.205 in revenue and CN¥5,022.752 in net income, now screens as a higher value score name. See our latest analysis for...

Kingboard Holdings (SEHK:148) has just posted FY 2025 results that put the focus squarely on profit quality, with first half revenue of HK$21.6b and basic EPS of HK$2.33, against a trailing twelve month backdrop of HK$45.4b in revenue and EPS of HK$3.97 that was heavily influenced by a HK$2.0b one off gain. Over the last few reporting halves, revenue has moved from HK$20.4b in 1H FY 2024 to HK$22.7b in 2H FY 2024 and then HK$21.6b in 1H FY 2025, while basic EPS shifted from HK$1.36 to HK$0.11...

Sunshine Insurance Group (SEHK:6963) opened FY 2025 with first half revenue of C¥38.5b and basic EPS of C¥0.29, against trailing 12 month revenue of C¥79.5b and EPS of C¥0.55, setting a clear earnings season marker for investors watching the stock at C¥3.63. Over the past few reporting periods, revenue has moved from C¥38.3b in the first half of 2024 to C¥40.3b in the second half of 2024 and C¥38.5b in the first half of 2025. Basic EPS shifted from C¥0.27 to C¥0.20 and then to C¥0.29, giving...

China Lilang (SEHK:1234) has put fresh numbers on the table, reporting FY 2025 first half revenue of C¥1.7b and basic EPS of C¥0.20, with trailing 12 month revenue at C¥4.1b and EPS at C¥0.42 framing the latest run rate. The company has seen revenue move from C¥1.6b and EPS of C¥0.23 in 1H 2024 to C¥2.0b and EPS of C¥0.15 in 2H 2024, setting up the current period against a backdrop where investors are already weighing earnings growth forecasts, slightly softer margins and an unstable dividend...

Haitian International Holdings (SEHK:1882) just reported its FY 2025 first half with revenue of C¥9.0b and basic EPS of C¥1.07, setting the tone against a trailing twelve month picture that includes C¥17.7b in revenue and EPS of C¥2.07. The company has seen revenue move from C¥8.0b in the first half of 2024 to C¥9.0b in the first half of 2025, while basic EPS has gone from C¥0.95 to C¥1.07 over the same period, all against a trailing net profit margin of 18.6% that leaves investors focused on...

Q Technology (Group) (SEHK:1478) has reported its FY 2025 first half results with revenue of C¥8.8b and basic EPS of C¥0.26, setting the stage against a year in which trailing twelve month EPS reached C¥1.26 on revenue of C¥20.9b and net income of C¥1.5b. The company has seen revenue move from C¥7.7b in 1H 2024 to C¥8.5b in 2H 2024 and then to C¥8.8b in 1H 2025, while basic EPS progressed from C¥0.10 to C¥0.14 and then to C¥0.26 over the same periods, giving investors an earnings season...

Tencent Holdings (SEHK:700) is back in focus after crowds lined up outside its headquarters to install OpenClaw, while the company also builds its own AI agent for the WeChat superapp. See our latest analysis for Tencent Holdings. Tencent’s HK$550.0 share price comes after a 3.38% 1 month share price return and a weaker 11.72% year to date share price return. The 1 year total shareholder return of 2.55% and 3 year total shareholder return of 64.02% point to stronger performance over a longer...

Dah Sing Banking Group (SEHK:2356) has scheduled a board committee meeting on 30 March 2026 to approve its consolidated 2025 annual results and consider a potential final dividend, an important date for investors monitoring income and capital strength. See our latest analysis for Dah Sing Banking Group. The upcoming results and dividend decision come after mixed recent share price moves, with a 12.43% 3 month share price return and a 10.25% year to date gain, while the 1 year total...

Shanghai Chicmax Cosmetic Co., Ltd. previously issued unaudited guidance for 2025, indicating expected revenue of about RMB 9,100.0 million to RMB 9,200.0 million and profit of roughly RMB 1,140.0 million to RMB 1,160.0 million, both showing strong year-on-year increases versus 2024. The company linked this outlook to the effectiveness of its multi-brand, multi-category approach, highlighting especially strong momentum from its KANS anti-aging skincare line and its infant-focused newpage...

WuXi Biologics (Cayman) (SEHK:2269) is back in focus after two recent developments: a collaboration with Earendil Labs on complex antibody and ADC programs, and a record showing at the 2026 Asia Pacific Biopharma Excellence Awards. See our latest analysis for WuXi Biologics (Cayman). Those Earendil and awards announcements arrive as momentum has been mixed, with a 12.85% 1 month share price return decline, a 90 day share price return of 8.73%, and a 1 year total shareholder return of...

Greentown China Holdings (SEHK:3900) has issued unaudited guidance indicating an expected 95% drop in 2025 profit attributable to owners, citing thinner gross margins, weaker joint venture contributions, and fresh asset impairment charges. See our latest analysis for Greentown China Holdings. The latest guidance lands after a period of mixed performance, with a 90 day share price return of 28.67% and a year to date share price return of 29.59%, but a 1 year total shareholder return of a...

Zhejiang Leapmotor Technology (SEHK:9863) just reported full year 2025 earnings, turning a loss into profit as sales reached CNY 64,731.86 million and net income came in at CNY 538.39 million. See our latest analysis for Zhejiang Leapmotor Technology. The latest earnings release comes after a period of mixed performance, with a 7 day share price return of 8.84% contrasting with a year to date share price return decline of 10.09% and a 3 year total shareholder return of 49.78%. This suggests...

Why Sichuan Baicha Baidao Industrial is in focus now Sichuan Baicha Baidao Industrial (SEHK:2555) has issued unaudited earnings guidance for 2025, flagging higher adjusted net profit and net profit compared with 2024, which puts its profitability and recent share performance under the spotlight for investors. See our latest analysis for Sichuan Baicha Baidao Industrial. The earnings guidance has arrived after a weak stretch for investors, with a 1 year total shareholder return decline of...

China Tobacco International (HK) (SEHK:6055) has caught investor attention after reporting full year 2025 results, alongside a proposed final cash dividend of HK$0.33 per share, pairing earnings information with a fresh income timeline. See our latest analysis for China Tobacco International (HK). The latest earnings and dividend news comes after a mixed price pattern, with a 1-day share price return of 1.41% against a 30-day share price return decline of 15.29%, yet a 1-year total...

Angelalign Technology (SEHK:6699) has issued fresh 2025 earnings guidance, projecting net profit of about US$24 million to US$30 million, compared with roughly US$10 million in 2024, highlighting stronger clear aligner demand and cost timing effects. See our latest analysis for Angelalign Technology. Angelalign Technology's shares have rallied in recent months, with a 90 day share price return of 17.51% and year to date share price return of 16.26%. However, the 3 year total shareholder...

Akeso (SEHK:9926) is back in focus after announcing that its trispecific antibody AK150 has received IND clearance from China’s NMPA, clearing the way for clinical trials in advanced solid tumors. See our latest analysis for Akeso. The AK150 IND clearance, together with recent cervical cancer data for cadonilimab and the GBM collaboration announcement, has coincided with a 5.81% 1 day share price return and a 12.44% 7 day share price return at a current share price of HK$116.6. The 1 year...

InnoCare Pharma recently dosed the first healthy volunteer in a China clinical trial of ICP-538, an oral VAV1-directed molecular glue degrader for autoimmune diseases, marking the first VAV1 degrader to reach trials in China and only the second globally. This move positions InnoCare at the forefront of a new class of targeted immunology drugs, in an area where no VAV1-focused therapies are yet approved worldwide. We’ll now examine how advancing ICP-538, a first-in-China VAV1 degrader, could...

Keymed Biosciences (SEHK:2162) is back in focus after partner AstraZeneca began a Phase III trial of CMG901 in advanced gastric and related cancers, triggering a US$45 million milestone payment to the group. See our latest analysis for Keymed Biosciences. The CMG901 Phase III update comes after a strong 1 year total shareholder return of 50.97%. Shorter term share price momentum is steadier, with a 7 day share price return of 6.36% around the HK$54.35 level. If you are looking for other...

China Mengniu Dairy (SEHK:2319) has issued preliminary 2025 guidance flagging a 7% to 8% revenue decline and a slightly lower operating margin, while also being removed from the Hang Seng China Enterprises Index. See our latest analysis for China Mengniu Dairy. The latest guidance and index removal come after a mixed share price pattern, with a 12.1% year to date share price return and a 12.5% 90 day share price return, but a 13.0% negative total shareholder return over the past year. This...

Shanghai Henlius Biotech (SEHK:2696) has drawn fresh attention after China’s National Medical Products Administration approved phase 1 trials for two solid tumour candidates, HLX316 and HLX3901, both backed by positive preclinical safety and efficacy data. See our latest analysis for Shanghai Henlius Biotech. The recent NMPA green light for HLX316 and HLX3901 comes as Shanghai Henlius Biotech’s share price sits at HK$67.95, with a 90 day share price return of 13.53% and a very large 3 year...

Genscript Biotech has reported its full-year 2025 results, with sales rising to US$959.53 million while the company moved from a prior-year net income of US$2.96 billion to a net loss of US$532.83 million, alongside higher basic and diluted losses per share. A key driver of this sharp swing in reported profitability is the absence of the previous year’s very large one-time unrealised gain from deconsolidation, which means the latest figures chiefly reflect the underlying operating profile...